All posts by: Michael Zand

Editas Medicine (EDIT) and OptiNose (OPTN) Financial Survey – StockNewsTimes

Editas Medicine (EDIT) and OptiNose (OPTN) Financial SurveyStockNewsTimesIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) co… Continue reading

Blindness gene therapy price tag stirs controversy – ModernMedicine

Blindness gene therapy price tag stirs controversyModernMedicine"Our own non-traditional distribution model—offering access through either Accredo or CuraScript—which we have leveraged successfully with other high cost therapies such as Spinraza, … Continue reading

Synthetic Biology Market Outlook to 2022: Top Companies in Market, Trends & Growth Factors and Details for Business … – MilTech

Synthetic Biology Market Outlook to 2022: Top Companies in Market, Trends & Growth Factors and Details for Business …MilTechSynthetic Biology Market in World, presents critical information and factual data about Synthetic Biology Industry, with a… Continue reading

Paragon Bioservices Expands Gene Therapy Manufacturing Capacity – Pharmaceutical Technology Magazine

Paragon Bioservices Expands Gene Therapy Manufacturing CapacityPharmaceutical Technology MagazineParagon Bioservices, a biologics contract development and manufacturing organization (CDMO) for gene therapy and vaccines, announced the expansion of a new… Continue reading

Paragon Bioservices Expands Gene Therapy Manufacturing Capacity – BioPharm International

OutSourcing-Pharma.comParagon Bioservices Expands Gene Therapy Manufacturing CapacityBioPharm InternationalParagon Bioservices, a biologics contract development and manufacturing organization (CDMO) for gene therapy and vaccines, announced the expansio… Continue reading

Personalized Dendritic Cell Vaccines Could Improve Cancer Immunotherapy – Genetic Engineering & Biotechnology News

Practical Considerations for Prescribing Immunotherapy – OncLive

OncLivePractical Considerations for Prescribing ImmunotherapyOncLiveThe question of when to use immunotherapy is an evolving one. As with any new treatment, you develop it in patients with advanced disease in the refractory setting. Right now, probably… Continue reading